The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the USA. In this retrospective study, we included adults (age ≥ 18 years) with R/R DLBCL who received lonca monotherapy as third- (3 L) or fourth line (4 L) treatment after progressing on second line (2 L) or 3 L CAR-T, respectively. Post-CAR-T lonca outcomes included response rates (overall response rate [ORR] and complete response [CR] rate), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 118 patients were included in the analysis with 95 receiving lonca following 2 L CAR-T (median age:66 years; 61% male) and 23 following 3 L CAR-T (median age:57 years; 43% male). Patients with 2 L CAR-T/3 L lonca had an ORR of 73% (CR rate of 34%). With a median follow-up of 8.5 months following lonca initiation, median DOR, PFS, and OS were not reached. The DOR, PFS, and OS at 12 months were 68%, 77%, and 84%, respectively. Patients with 3 L CAR-T/4 L lonca had an ORR of 78% (CR rate of 17%). With a median follow-up of 13 months following lonca initiation, the median DOR and PFS were 7.6 and 12.0 months, while median OS was not reached. OS at 12 months was 95%. In this study, we found that lonca monotherapy was an effective treatment option in R/R DLBCL in 3 L and 4 L settings including those who were resistant to or progressed after CAR-T.

嵌合抗原受体 T 细胞疗法 （CAR-T） 进展/失败后 loncastuximab tesirine （lonca） 的疗效尚不清楚。因此，我们试图检查 CAR-T 后 lonca 在美国复发或难治性 （R/R） 弥漫性大 B 细胞淋巴瘤 （DLBCL） 患者中的实际使用和结果。在这项回顾性研究中，我们纳入了患有 R/R DLBCL 的成人 （≥ 18 岁），这些患者在二线 （2 L） 或 3 L CAR-T 进展后分别接受了 lonca 单药治疗作为三线 （3 L） 或四线 （4 L） 治疗。CAR-T lonca 后结局包括缓解率 （总缓解率 [ORR] 和完全缓解 [CR] 率 ）、缓解持续时间 （DOR） 、无进展生存期 （PFS） 和总生存期 （OS）。共有 118 名患者被纳入分析，其中 95 名患者在 2 L CAR-T 后接受 lonca 治疗 （中位年龄：66 岁;61% 为男性），23 名患者在 3 L CAR-T 后接受治疗 （中位年龄：57 岁;43% 为男性）。2 L CAR-T/3 L lonca 患者的 ORR 为 73% （CR 率为 34%）。lonca 开始后中位随访 8.5 个月，中位 DOR 、 PFS 和 OS 未达到。12 个月时的 DOR 、 PFS 和 OS 分别为 68% 、 77% 和 84%。3 L CAR-T/4 L lonca 患者的 ORR 为 78% （CR 率为 17%）。lonca 开始后中位随访 13 个月，中位 DOR 和 PFS 分别为 7.6 个月和 12.0 个月，而中位 OS 未达到。12 个月时的 OS 为 95%。在这项研究中，我们发现 lonca 单药治疗是 3 L 和 4 L 环境中 R/R DLBCL 的有效治疗选择，包括那些对 CAR-T 耐药或在 CAR-T 后进展的患者。